

Laising Yen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9918588/publications.pdf>

Version: 2024-02-01

11
papers

771
citations

1307594

7
h-index

1372567

10
g-index

12
all docs

12
docs citations

12
times ranked

1531
citing authors

#	ARTICLE	IF	CITATIONS
1	Chimeric RNA Design Principles for RNA-Mediated Gene Fusion. <i>Cells</i> , 2022, 11, 1002.	4.1	0
2	RNA-driven JAZF1-SUZ12 gene fusion in human endometrial stromal cells. <i>PLoS Genetics</i> , 2021, 17, e1009985.	3.5	6
3	Validating Gene Fusion as the Source of Chimeric RNAs. <i>Methods in Molecular Biology</i> , 2020, 2079, 187-207.	0.9	1
4	RNA-mediated gene fusion in mammalian cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E12295-E12304.	7.1	25
5	The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells. <i>Journal of Hematology and Oncology</i> , 2018, 11, 74.	17.0	60
6	Noncoding Effects of Circular RNA CCDC66 Promote Colon Cancer Growth and Metastasis. <i>Cancer Research</i> , 2017, 77, 2339-2350.	0.9	538
7	The in vitro selection world. <i>Methods</i> , 2016, 106, 3-13.	3.8	41
8	Recurrent <i>BCAM-AKT2</i> fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1272-7.	7.1	42
9	Aberrant MUC1-TRIM46-KRTCAP2 Chimeric RNAs in High-Grade Serous Ovarian Carcinoma. <i>Cancers</i> , 2015, 7, 2083-2093.	3.7	15
10	CDKN2D-WDFY2 Is a Cancer-Specific Fusion Gene Recurrent in High-Grade Serous Ovarian Carcinoma. <i>PLoS Genetics</i> , 2014, 10, e1004216.	3.5	41
11	A Mammalian Cell-Based Assay for Screening Inhibitors of RNA Cleavage. <i>Methods in Molecular Biology</i> , 2009, 540, 335-347.	0.9	2